keyword
https://read.qxmd.com/read/38395750/association-between-colorectal-cancer-the-frequency-of-bacteroides-fragilis-and-the-level-of-mismatch-repair-genes-expression-in-the-biopsy-samples-of-iranian-patients
#21
JOURNAL ARTICLE
Nooshin Nazarinejad, Bahareh Hajikhani, Amir Abbas Vaezi, Farzaneh Firoozeh, Fatemeh Sameni, Somayeh Yaslianifard, Mehdi Goudarzi, Masoud Dadashi
BACKGROUND: Deficient DNA mismatch repair (MMR) can cause microsatellite instability (MSI) and is more common in colorectal cancer (CRC) patients. Understanding the carcinogenic mechanism of bacteria and their impact on cancer cells is crucial. Bacteroides fragilis (B. fragilis) has been identified as a potential promoter of tumorigenesis through the alteration of signaling pathways. This study aims to assess the expression levels of msh2, msh6, mlh1, and the relative frequency of B. fragilis in biopsy samples from CRC patients...
February 23, 2024: BMC Gastroenterology
https://read.qxmd.com/read/38394410/clinicopathological-features-and-evaluation-of-microsatellite-stability-of-colorectal-carcinoma-with-cribriform-comedo-pattern
#22
JOURNAL ARTICLE
Tuğba Günler, Pinar Karabağli, Hicret Tiyek, Özge Keskin, Muslu K Körez
BACKGROUND: Cribriform comedo-type adenocarcinoma (CCA) was a colon cancer subtype defined in the 2009 World Health Organization (WHO) classification. In the 2018 classification, it was a colon cancer subtype included in the adenocarcinoma, Not otherwise specified (NOS) group. A few studies have reported that colon cancers with a cribriform pattern have worse overall survival, and most of them are microsatellite stable (MSS). In this study, we evaluated CCAs based on their clinicopathologic features and microsatellite stability...
November 9, 2023: Indian Journal of Pathology & Microbiology
https://read.qxmd.com/read/38342956/pan-cancer-analysis-reveals-potential-immunological-and-prognostic-roles-of-mettl7a-in-human-cancers
#23
JOURNAL ARTICLE
Bin Wang, Jingjing Jiang, Danju Luo, Xiong Wang
Methyltransferase-like protein 7A (METTL7A) is an m6A RNA methyltransferase that has been linked to cancer prognosis and drug resistance. However, a comprehensive analysis of METTL7A is lacking. The expression of METTL7A, prognostic performance, correlation with microsatellite instability (MSI), tumor mutational burden (TMB), and immune infiltration was investigated in The Cancer Genome Atlas (TCGA). Immunohistochemistry staining was applied to detect METTL7A in 6 tumors. METTL7A was significantly decreased in 19 cancers in TCGA including LUAD...
February 12, 2024: Scientific Reports
https://read.qxmd.com/read/38313961/large-cell-neuroendocrine-carcinoma-presenting-as-adult-intussusception
#24
John O Agboola, Hagar Attia, Li Zhonghua, Meredith Pittman
Large cell neuroendocrine carcinoma (LCNEC) is an extremely rare malignant tumor of the colon, presenting with more severe clinical outcomes in comparison to colonic adenocarcinoma. There are very few reported cases in the literature. We hereby add our voice to the incidence of this disease by presenting the first report of a patient with ileocolic intussusception secondary to a large cell neuroendocrine cancer of the cecum. The patient was a 48-year-old woman who presented with acute onset of generalized abdominal pain and leukocytosis...
January 2024: Curēus
https://read.qxmd.com/read/38312843/development-and-verification-of-a-combined-immune-and-cancer-associated-fibroblast-related-prognostic-signature-for-colon-adenocarcinoma
#25
JOURNAL ARTICLE
Jingsun Wei, Xiaoxu Ge, Yucheng Qian, Kai Jiang, Xin Chen, Wei Lu, Hang Yang, Dongliang Fu, Yimin Fang, Xinyi Zhou, Qian Xiao, Yang Tang, Kefeng Ding
INTRODUCTION: To better understand the role of immune escape and cancer-associated fibroblasts (CAFs) in colon adenocarcinoma (COAD), an integrative analysis of the tumor microenvironment was performed using a set of 12 immune- and CAF-related genes (ICRGs). METHODS: Univariate and least absolute shrinkage and selection operator (LASSO) Cox regression analyses were used to establish a prognostic signature based on the expression of these 12 genes ( S1PR5 , AEN , IL20RB , FGF9 , OSBPL1A , HSF4 , PCAT6 , FABP4 , KIF15 , ZNF792 , CD1B and GLP2R )...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38311637/construction-and-validation-of-a-colon-cancer-prognostic-model-based-on-tumor-mutation-burden-related-genes
#26
JOURNAL ARTICLE
Daoyang Zou, Tianwen Xu
Currently, immunotherapy has entered the clinical diagnosis and treatment guidelines for colon cancer, but existing immunotherapy markers cannot predict the effectiveness of immunotherapy well. This study utilized the TCGA-COAD queue to perform differential gene analysis on high and low-mutation burden samples, and screen differentially expressed genes (DEGs). To explore new molecular markers or predictive models of immunotherapy by using DEGs for NMF classification and prognostic model construction. Through systematic bioinformatics analysis, the TCGA-COAD cohort was successfully divided into high mutation burden subtypes and low mutation burden subtypes by NMF typing using DEGs...
February 4, 2024: Scientific Reports
https://read.qxmd.com/read/38303358/-a-case-of-pathologic-complete-response-achieved-with-preoperative-pembrolizumab-therapy-for-transverse-colon-cancer
#27
JOURNAL ARTICLE
Yo Akazawa, Hajime Hirose, Shu Okamura, Hiroshi Takeyama, Risa Kawamoto, Narumi Sawamura, Satomi Sakai, Sakina Hashizume, Masahiro Koh, Koji Hayashi, Akio Hara, Yoshiteru Katsura, Setsuko Yoshioka, Chikara Ebisui, Masahiko Yano
A 77-year-old female patient presented with a medical history of 4 cancerous lesions, each with a surgical history. She was referred to our hospital due to anemia. Upon examination, she was diagnosed with transverse colon cancer. Duodenal invasion was suspected, which made performing R0 surgery difficult; therefore, the NAC approach was chosen. Three courses of CAPOX were administered, resulting in tumor obstruction, leading to the formation of an ileum stoma. MSI testing revealed MSI-H, and pembrolizumab treatment was initiated...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38303314/-axillary-lymph-node-recurrence-after-curative-surgery-for-transverse-colon-cancer-a-case-report
#28
JOURNAL ARTICLE
Fumitaka Nakayama, Yusuke Asada, Kaori Kameyama, Taketo Yamada, Takashi Takenoya, Ippei Oto, Tetsuya Nakamura, Koji Osumi, Noriaki Kameyama
We report the rare case of an 89-year-old female with axillary lymph node recurrence after curative surgery for transverse colon cancer who had undergone right hemicolectomy with D3 lymphadenectomy with an uneventful postoperative course. Pathological examination confirmed the tumor's status as tub2>sig, T4aN3M0, and pStage Ⅲc, and signet-ring cell carcinoma was remarkably found in the metastatic lymph node. Genetic testing revealed wild-type RAS, a BRAF mutation, and a high MSI. After 9 months of follow-up without adjuvant chemotherapy, CEA increased sharply to 41...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38303268/-a-case-of-response-to-pembrolizmab-in-unresectable-msi-high-transverse-colon-cancer
#29
JOURNAL ARTICLE
Miki Shindo, Yoshinori Kagawa, Yujiro Nishizawa, Akira Inoue, Yuki Ozato, Akinori Kumode, Masumi Santo, Yuki Ueda, Miho Kimura, Akiko Fukui, Yasuhiro Miyazaki, Akira Tomokuni, Masaaki Motoori, Kazuhiro Iwase, Kazumasa Fuzitani
A 80s man was diagnosed circulated type 2 colon cancer at the transverse colon, and pathological findings was adenocarcinoma( por1). Genomic findings were microsatellite instability-high(MSI-H), all RAS wild type and BRAFV600E mutated. Contrast-enhanced CT showed an enlarged lymph nodes(#221, #222, #223, #214)along the middle colic and superior mesenteric artery. Clinical diagnosis was a locally advanced unresectable transverse colon cancer, cT4aN3M1a(LYM), cStage Ⅳa. Drug therapy with pembrolizumab was prescribed...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38303267/-a-case-of-pathological-complete-response-for-msi-high-locally-advanced-unresectable-transverse-colon-cancer-treated-with-nivolumab-plus-ipilimumab-combination-therapy
#30
JOURNAL ARTICLE
Yujiro Nishizawa, Yoshinori Kagawa, Akira Inoue, Yuki Ozato, Akinori Kumode, Yuki Ueda, Megumi Takahashi, Akiko Fukui, Hisateru Komatsu, Masashi Hirota, Yasuhiro Miyazaki, Akira Tomokuni, Masaaki Motoori, Kazuhiro Iwase, Kazumasa Fujitani
74-year-old woman was diagnosed with locally advanced unresectable transverse colon cancer. She started CAPOX therapy as first-line therapy after ileostomy. After second course, MSI-high was detected, so nivolumab plus ipilimumab combination therapy was started as second-line therapy. After 4 courses of combination therapy, she was judged to be in partial response and surgery was performed. Histopathological diagnosis of the surgical specimen showed complete response, and she is still alive without recurrence 15 months after surgery...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38303246/-two-cases-suspected-of-lynch-syndrome-caused-by-juvenile-rectal-cancer
#31
JOURNAL ARTICLE
Naoki Aomatsu, Gen Tsujio, Keiho Aomatsu
Case 1: A 28-year-old man was admitted to our hospital because of bloody stools that persisted for several months. Colonoscopy showed a 1/2 circumferential type 2 tumor in the rectum. Laparoscopic high anterior resection(D3)was performed for rectal cancer cT3N0M0, cStage Ⅱa. The final diagnosis was pStage Ⅱa, and MSI-high. XELOX therapy was performed for 3 months to prevent recurrence, and the patient is alive without recurrence. Case 2: A 51-year-old man, father of case 1 patient, was admitted to our hospital because of anemia and dyspnea...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38303192/-a-case-of-msi-high-sigmoid-colon-cancer-in-which-long-term-survival-was-achieved-by-pembrolizumab-for-recurrent-lesions-resistant-to-conventional-chemotherapy
#32
JOURNAL ARTICLE
Hideaki Tsumuraya, Akinao Kaneta, Shotaro Fujita, Souhei Hayashishita, Shotaro Mochizuki, Hiroya Suzuki, Chiaki Takiguchi, Akira Matsuishi, Yuuya Maruyama, Ryo Kanouda, Mei Sakuma, Wataru Sakamoto, Tomoyuki Monma, Zenichiro Saze, Koji Kono
The patient underwent sigmoidectomy with D3 lymph node dissection and partial bladder resection for sigmoid colon cancer(cT4bN1M0, cStage Ⅲa), after preoperative chemotherapy with mFOLFOX plus panitumumab, and FOLFOXIRI plus bevacizumab. Postoperative adjuvant chemotherapy was performed by 8 courses of CAPOX. He relapsed hilar lymph nodes and peritoneal dissemination after 13 months after surgery, he underwent resection of the recurrent lesions. Four months after, he developed recurrence in liver and peritoneum...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://read.qxmd.com/read/38293978/-a-pan-cancer-analysis-of-ttc9a-expression-level-and-its-correlation-with-prognosis-and-immune-microenvironment
#33
JOURNAL ARTICLE
Y Yao, J Liu, X Zhou, Z Liu, S Qiu, Y He, X Zhou
OBJECTIVE: To investigate the expression level of tetratricopeptide repeat protein 9A in tumors and its association with the patients' prognosis and immune infiltration. METHODS: TTC9A expression in different tumor tissues and its association with prognosis, DNA methylation, tumor mutation burden (TMB), and microsatellite instability (MSI) were analyzed based on data from TCGA and GTEx. TIMER and xCell were used to analyze the relationship between TTC9A expression and immune infiltration...
January 20, 2024: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://read.qxmd.com/read/38278008/cross-trial-comparisons-for-the-adjuvant-treatment-of-msi-colorectal-cancer-dare-to-dream-the-future-scenarios
#34
JOURNAL ARTICLE
Alessandro Pastorino, Fabio Catalano, John R Zalcberg, Alberto Sobrero
The remarkable outcomes achieved with neoadjuvant checkpoint inhibitors for patients diagnosed with MSI colorectal cancer hold the potential to revolutionize the treatment landscape in this context. Specifically, the combination of nivolumab plus ipilimumab in colon cancer and dostarlimab in rectal cancer has led to an unprecedented rate of complete pathological and clinical responses. Notably, these responses have been further substantiated by the absence of relapses, with a 0% relapse rate observed during the first year of follow-up...
March 2024: European Journal of Cancer
https://read.qxmd.com/read/38270484/ras-mutations-predict-recurrence-free-survival-and-recurrence-patterns-in-colon-cancer-a-unicenter-study-in-morocco
#35
JOURNAL ARTICLE
Fatima El Agy, Sanae El Bardai, Sara Boukansa, Laila Bouguenouch, Zineb Benbrahim, Khalid Mazaz, El Bachir Benjelloun, Abdelmalek Ousadden, Karim Ouldim, Sidi Adil Ibrahimi, Laila Chbani
PURPOSE: To date, only a few studies have investigated the role of molecular alterations in cancer recurrence. This exploratory study aimed to evaluate the impact of molecular alterations on the time and site of recurrence in patients with stage I-IV CRC and to identify the risk factors predicting recurrence-free survival in colon cancer. METHODS: A total of 270 patients were retrospectively included. We assessed the full RAS status using Sanger and pyrosequencing...
2024: Cancer Control: Journal of the Moffitt Cancer Center
https://read.qxmd.com/read/38205076/deficient-mismatch-repair-microsatellite-unstable-colorectal-cancer-therapeutic-advances-and-questions
#36
REVIEW
Baptiste Cervantes, Thierry André, Romain Cohen
The microsatellite instability (MSI) phenotype is related to a deficiency of the DNA mismatch repair (dMMR) system and is observed in 5% of metastatic colorectal cancers (mCRCs). MSI/dMMR phenotype testing should be routine for all CRCs regardless of stage. Two complementary techniques with a high concordance (90-97%) allow us to determine the MSI/dMMR status of a tumor: immunohistochemistry and polymerase chain reaction. Since 2020 and the results of the phase III KEYNOTE 177 trial, pembrolizumab [anti-programmed cell death protein 1 (PD1)] is the new standard of care in first-line MSI/dMMR mCRC...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38185290/clinical-molecular-characteristics-and-post-translational-modifications-of-colorectal-cancer-in-north-china-implications-for-future-targeted-therapies
#37
JOURNAL ARTICLE
Yajing Chi, Hongtu Yuan, Qing Fan, Zhendan Wang, Zuoxing Niu, Jinming Yu, Dandan Yuan
This study delineated the elucidate molecular changes and their post-translational modifications (PTMs) in heterogenetic colorectal cancer (CRC) for a deeper understanding of the CRC pathophysiology and identifying potential therapeutic targets. In this retrospective study, the profiles of 13 hot spot gene mutations were analyzed and the microsatellite instability (MSI) status was determined.Employing the Circulating Single-Molecule Amplification and Resequencing Technology (cSMART) assay, the clinical-pathological features of CRC were characterized in 249 Chinese patients...
January 5, 2024: Gene
https://read.qxmd.com/read/38178618/comprehensive-characterization-of-pkhd1-mutation-in-human-colon-cancer
#38
JOURNAL ARTICLE
Lu Han, Fangming Gong, Xuxiaochen Wu, Wanxiangfu Tang, Hua Bao, Yue Wang, Daizhenru Wang, Yulan Sun, Peng Li
INTRODUCTION: The PKHD1 (Polycystic Kidney and Hepatic Disease 1) gene is essential for producing fibrocystin or polyductin, which is crucial in various cellular functions. Mutations in PKHD1 have been found to be involved in the development and progression of colorectal cancer (CRC). Along with APC, TP53, and KRAS, PKHD1 is one of the most frequently mutated genes in CRC. PKHD1 expression is governed by the Wnt/PCP pathway, often dysregulated in CRC. Targeting this pathway, crucial for CRC progression, could unveil potential therapeutic strategies for colon cancer treatment...
January 4, 2024: Cancer Medicine
https://read.qxmd.com/read/38175383/pole-mutant-colon-adenocarcinoma-case-presentation-and-histopathological-evaluation
#39
JOURNAL ARTICLE
Tamás Pancsa, Béla Vasas, Zsombor Melegh, Erika Tóth, László Torday, Anita Sejben
INTRODUCTION: POLE mutant phenotype in colon adenocarcinomas represents a rare molecular subtype. These tumours are generally responsive to immune-checkpoint inhibition therapy and, therefore, are currently considered as a subtype with good prognosis. We hereby present the first detailed case presentation of a POLE mutant colon adenocarcinoma with useful microscopic features. CASE REPORT: A 53-year-old male patient's colon adenocarcinoma histologically showed wide variety of growth patterns and massive intra- and peritumoural lymphocytic infiltrate...
January 4, 2024: Journal of Gastrointestinal Cancer
https://read.qxmd.com/read/38110279/-analysis-of-clinicopathological-features-and-prognosis-of-sporadic-synchronous-multiple-primary-colorectal-cancers
#40
JOURNAL ARTICLE
Z F Qin, G H Xu, S Q Zhou, P W Zheng, Y P Zhu, H X Ju, D C Li, D N Ma
Objective: To investigate the impact of relative locations of multiple foci and microsatellite status of sporadic, synchronous, multiple, primary, colorectal carcinomas on clinicopathological features and prognosis. Methods: The clinicopathologic and prognostic data of 278 patients with sporadic, synchronous, multiple, primary, colorectal carcinomas who had been admitted to the Department of Colorectal Surgery at Zhejiang Cancer Hospital from January 2008 to July 2022 were retrospectively collected. The patients were categorized into three groups based on the relative locations of their multiple cancer foci: (1) a right-sided group that comprised patients with multiple cancer foci in the cecum, ascending colon, hepatic flexure of the colon, and transverse colon; (2) a left-sided group that comprised patients with multiple cancer foci in the splenic flexure of the colon, descending colon, sigmoid colon, and rectum; and (3) a left- and right-sided group that comprised patients with multiple cancer foci in the right half of the colon and left half of the colon/rectum...
December 25, 2023: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
keyword
keyword
111143
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.